As HIV, TB and other treatments are updated in our public healthcare system, it is critical that healthcare workers and counsellors stay on top of the latest developments. One innovative programme makes use of short lessons delivered over WhatsApp to provide such training. Sue Segar reports.
A child-friendly formulation of the antiretroviral drug dolutegravir was first included in the country’s HIV treatment guidelines in 2023. New estimates suggest that most children aged one to four living with HIV have now been switched to the drug, reports Elri Voigt.
Massive gains have been made in reducing new HIV infections and deaths in children. Yet, many of the statistics for children still look worse than those for adults. Elri Voigt asked experts why this is the case and what factors prevent children living with HIV from starting and staying on the treatment that can keep them healthy.
Over the last two decades, South Africa made massive progress in reducing transmission of HIV from mothers to their babies. Even so, about 7 000 babies still contract the virus every year. Experts put this down to having the right puzzle pieces for prevention but failing to integrate them optimally. Elna Schütz reports.
Research led by Professor Adrie Bekker is paving the way for an important HIV medicine to be made available to neonates in a way that is both safe and much more convenient than previous options. Biénne Huisman met with the passionate clinician-scientist at her office in Cape Town.
That HIV can develop resistance to the drugs used to treat it is nothing new, but results from recent studies reveal the emergence of resistance in subsets of people living with HIV to dolutegravir – an antiretroviral widely used in South Africa. Top HIV experts spoke to Elri Voigt about the new findings and what it means for people living with HIV in the country.
In December 2008, Dr Mark Blaylock left South Africa after a high-profile spat with then-Health MEC of KwaZulu-Natal Peggy Nkonyeni. The affair was sparked by Blaylock’s colleague Colin Pfaff being charged with misconduct for sourcing funding for antiretroviral drugs for pregnant women living with HIV. Four years later, Blaylock was back at Manguzi District Hospital in KwaZulu-Natal. Sue Segar chatted to Blaylock about his years outside of South Africa, returning to Manguzi, and how healthcare in KwaZulu-Natal has changed over the years.
In what is likely one of the largest treatment rollouts in South African history, well over four million people living with HIV have started taking the antiretroviral dolutegravir since its introduction around four years ago. Now, according to a recent study published in the Lancet medical journal, use of dolutegravir in South Africa is associated with more people staying on treatment and higher rates of viral suppression. Elri Voigt unpacks the study findings and assesses progress in the country’s switch to dolutegravir-based HIV treatment.
The 11th SA AIDS conference, recently held in Durban, highlighted the worrying fact that key HIV numbers such as treatment coverage are much lower in children than in adults. But as Elri Voigt reports, conference delegates also heard about new treatments and guidelines that will make life easier for kids and the exciting potential of several new long-acting experimental treatments.
A study published last year on an HIV variant that has been circulating in the Netherlands for the last 20 years reminded the public of the existence of viral variants beyond SARS-CoV-2. Elri Voigt unpacks what we know about the HI-virus, its variants, and the study’s findings.
New child-friendly formulations of several important antiretroviral medicines were recently approved by the South African Health Products Regulatory Authority. Thabo Molelekwa asks what this means for children living with HIV in South Africa and how long it will take for these medicines to become widely available.
In 2019, the Department of Health started providing the antiretroviral drug dolutegravir as part of HIV treatment in the public sector. Three years later, close to 3.2 million people in South Africa are taking dolutegravir every day. Even so, the rollout of dolutegravir hasn’t all been smooth sailing. Elri Voigt investigates how the massive undertaking of switching millions of people to a new drug has gone.
